Unconslidated revenue → Revenue: $44.9BRevenue → Cost of revenue: $25.4BLab Products and Biopharma → Unconslidated revenue: $22.5BRevenue → Gross profit: $19.5BLife Science Solutions → Unconslidated revenue: $13.5BGross profit → Operating expenses: $8.7BGross profit → Operating profit: $8.4BOperating expenses → SG&A: $7.1BOperating profit → Net profit: $7.0BAnalytical Instruments → Unconslidated revenue: $6.6BSpeciality Diagnostics → Unconslidated revenue: $4.8BUnconslidated revenue → Eliminations: $2.5BGross profit → Amortization of acquisition-related intangible assets: $2.4BOperating expenses → R&D: $1.5BOperating profit → Tax: $0.7BOperating profit → Interest: $0.5BOperating profit → Losses of unconsolidated entities: $0.2BOperating expenses → Restructuring & other: $0.1BOperating profit → Other: $0.1BLife Science Solutions: $13.5BUnconslidated revenue: $47.4BAnalytical Instruments: $6.6BSpeciality Diagnostics: $4.8BLab Products and Biopharma: $22.5BRevenue: $44.9BEliminations: $2.5BGross profit: $19.5BCost of revenue: $25.4BOperating profit: $8.4BOperating expenses: $8.7BNet profit: $7.0BTax: $0.7BInterest: $0.5BOther: $0.1BLosses of unconsolidated entities: $0.2BR&D: $1.5BSG&A: $7.1BRestructuring & other: $0.1BAmortization of acquisition-related intangible assets: $2.4Bcreated with SankeyArt.comLife Science Solutions$13.5B-13% Y/YUnconslidated revenue$47.4B11% Y/YAnalytical Instruments$6.6B0% Y/YSpeciality Diagnostics$4.8B-16% Y/YLab Products and Biopharma$22.5B51% Y/YRevenue$44.9B15% Y/YEliminations$2.5B-16% Y/YGross profit$19.5B-4% Y/YCost of revenue$25.4B34% Y/YOperating profit$8.4B-16% Y/YOperating expenses$8.7B3% Y/YNet profit$7.0B-10% Y/YTax$703M-37% Y/YInterest$454MOther$104MLosses of unconsolidated entities$172MR&D$1.5B5% Y/YSG&A$7.1B4% Y/YRestructuring & other$114M-42% Y/YAmortization of acquisition-related intangible assets$2.4B36% Y/YThermo Fisher Scientific FY22 Income Statement
Copy and edit diagram